FTO and hepatocellular carcinoma: For example, Xu et al. found that METTL3/FTO/YTHDF1/2-mediated m6A modification can enhance the stability of circRNA-SORE and induce sorafenib resistance in hepatocellular carcinoma (HCC) [11].